Unichem Laboratories moves up on getting ANDA approval for Prasugrel Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Unichem Laboratories is currently trading at Rs. 418.25, up by 1.15 points or 0.28% from its previous closing of Rs. 417.10 on the BSE.
The scrip opened at Rs. 422.00 and has touched a high and low of Rs. 422.00 and Rs. 415.75 respectively. So far 1799 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 467.00 on 03-Nov-2022 and a 52 week low of Rs. 265.00 on 25-Jan-2023.
Last one week high and low of the scrip stood at Rs. 422.00 and Rs. 409.80 respectively. The current market cap of the company is Rs. 2944.72 crore.
The promoters holding in the company stood at 50.93%, while Institutions and Non-Institutions held 11.26% and 37.80% respectively.
Unichem Laboratories has received ANDA approval for its Prasugrel Tablets USP, 5 mg and 10 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Effient (Prasugrel) Tablets, 5 mg and 10 mg, of Cosette Pharmaceuticals, Inc.
Prasugrel tablets are indicated to reduce the rate of thrombotic CV events (including stent thrombosis) in patients with acute coronary syndrome. The product will be commercialized from Unichem’s Goa Plant.
Unichem Laboratories is an international, integrated, specialty pharmaceutical company.
